DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences (Q38040883)

27 August 2017

DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences (English)

1 reference

27 August 2017

0 references

acute myeloid leukemia

1 reference

Xavier Thomas

1

1 reference

PubMed ID

22950862

27 August 2017

language of work or name

English

0 references

publication date

5 September 2012

1 reference

Expert Opinion on Drug Discovery

27 August 2017

1 reference

27 August 2017

7

1 reference

27 August 2017

11

1 reference

27 August 2017

1039-1051

1 reference

DNA methylation, methyltransferases, and cancer

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

DNA Methylation and Gene Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Cytosine methylation and the ecology of intragenomic parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Preferential methylation of unmethylated DNA by Mammalian de novo DNA methyltransferase Dnmt3a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

The PWWP domain of Dnmt3a and Dnmt3b is required for directing DNA methylation to the major satellite repeats at pericentric heterochromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Modulation of Dnmt3b function in vitro by interactions with Dnmt3L, Dnmt3a and Dnmt3b splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Solving the Dnmt2 enigma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Mammalian DNA methyltransferases: a structural perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Isolation and initial characterization of a novel zinc finger gene, DNMT3L, on 21q22.3, related to the cytosine-5-methyltransferase 3 gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Number of CpG islands and genes in human and mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

DNA hypermethylation in tumorigenesis: epigenetics joins genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Gene silencing in cancer in association with promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Epigenetic modifications as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Epigenetic protein families: a new frontier for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Protein methyltransferases as a target class for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Epstein-Barr virus infection as an epigenetic driver of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

ICF syndrome mutations cause a broad spectrum of biochemical defects in DNMT3B-mediated de novo DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Acquired mutations in TET2 are common in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Iron control of erythroid development by a novel aconitase-associated regulatory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

The Polycomb group protein EZH2 directly controls DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Structure and function of mammalian DNA methyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

The mechanism of DNA cytosine-5 methylation. Kinetic and mutational dissection of Hhai methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Advances in the computational development of DNA methyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

DNA methyltransferase inhibitors and the development of epigenetic cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Epigenetic drug discovery: targeting DNA methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

5-AZA-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Decitabine: a historical review of the development of an epigenetic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Zebularine: A Novel DNA Methylation Inhibitor that Forms a Covalent Complex with DNA Methyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Zebularine: a new drug for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Flavonoids influence epigenetic-modifying enzyme activity: structure - function relationships and the therapeutic potential for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Potential roles of antisense technology in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Virtual screening of chemical libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Structure-based virtual ligand screening: recent success stories

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

DNA methyltransferase inhibitors-state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Measurement of genome wide DNA methylation by reversed-phase high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Capillary electrophoretic analysis of genomic DNA methylation levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Tumour class prediction and discovery by microarray-based DNA methylation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

The rationale and use of hypomethylation agents in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Preferential response of cancer cells to zebularine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Histone deacetylase inhibitors in programmed cell death and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

Combining Ligand- and Structure-Based Methods in Drug Design Projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2012.722618

10.1517/17460441.2012.722618

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22950862